Literature DB >> 29059512

Corrigendum.

.   

Abstract

Year:  2017        PMID： 29059512      PMCID： PMC6886022          DOI： 10.1111/jdv.14529

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  1 in total

1.  Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.

Authors:  A Blauvelt; K A Papp; H Sofen; M Augustin; G Yosipovitch; N Katoh; U Mrowietz; M Ohtsuki; Y Poulin; D Shrom; R Burge; K See; L Mallbris; K B Gordon
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-03-31       Impact factor: 6.166
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.